Analysts at Deutsche Bank started coverage on shares of Intercept Pharmaceuticals (NASDAQ:ICPT) in a research note issued on Tuesday. The firm set a “buy” rating and a $106.00 price target on the biopharmaceutical company’s stock. Deutsche Bank’s price target would suggest a potential upside of 65.11% from the stock’s current price.

Several other brokerages have also weighed in on ICPT. ValuEngine raised shares of Intercept Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Wedbush reaffirmed an “outperform” rating and set a $253.00 price target on shares of Intercept Pharmaceuticals in a research report on Friday, August 25th. BidaskClub raised shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, August 24th. BMO Capital Markets reaffirmed an “outperform” rating and set a $221.00 price target on shares of Intercept Pharmaceuticals in a research report on Wednesday, September 13th. Finally, Robert W. Baird reaffirmed an “outperform” rating and set a $332.00 price target on shares of Intercept Pharmaceuticals in a research report on Wednesday, September 13th. Four analysts have rated the stock with a sell rating, ten have given a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $142.40.

Intercept Pharmaceuticals (NASDAQ ICPT) traded up $3.56 during midday trading on Tuesday, reaching $64.20. 1,362,500 shares of the company’s stock traded hands, compared to its average volume of 767,989. The company has a debt-to-equity ratio of 3.15, a quick ratio of 5.95 and a current ratio of 5.95. Intercept Pharmaceuticals has a 1 year low of $54.98 and a 1 year high of $135.59.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($2.89) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($3.48) by $0.59. The company had revenue of $41.33 million for the quarter, compared to analyst estimates of $36.95 million. Intercept Pharmaceuticals had a negative net margin of 344.74% and a negative return on equity of 176.51%. The company’s revenue was up 697.9% on a year-over-year basis. During the same period in the prior year, the firm earned ($3.59) earnings per share. equities research analysts anticipate that Intercept Pharmaceuticals will post -13.35 EPS for the current year.

In related news, CEO Mark Pruzanski sold 1,532 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $58.87, for a total value of $90,188.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last quarter, insiders sold 2,566 shares of company stock valued at $151,025. 9.20% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of ICPT. WFG Advisors LP raised its holdings in Intercept Pharmaceuticals by 16.4% during the 2nd quarter. WFG Advisors LP now owns 888 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 125 shares during the last quarter. IFP Advisors Inc raised its holdings in Intercept Pharmaceuticals by 90.9% during the 3rd quarter. IFP Advisors Inc now owns 2,482 shares of the biopharmaceutical company’s stock worth $144,000 after purchasing an additional 1,182 shares during the last quarter. Aperio Group LLC bought a new position in Intercept Pharmaceuticals during the 2nd quarter worth approximately $212,000. SG Americas Securities LLC bought a new position in Intercept Pharmaceuticals during the 2nd quarter worth approximately $235,000. Finally, QCM Cayman Ltd. bought a new position in Intercept Pharmaceuticals during the 2nd quarter worth approximately $237,000. Institutional investors and hedge funds own 73.80% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Intercept Pharmaceuticals (ICPT) Now Covered by Deutsche Bank” was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/12/14/intercept-pharmaceuticals-icpt-now-covered-by-deutsche-bank.html.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.